Promising Results for mRNA Cancer Vaccine in Melanoma Trial
By Editor • August 19, 2026 • 1 min read
Moderna and Merck have reported significant success in their Phase 3 clinical trial for a personalized mRNA cancer vaccine, targeting unique mutations in melanoma patients.
This trial involved 1,137 individuals with advanced melanoma, who received either the tailored vaccine combined with Merck's Keytruda or Keytruda alone. The findings, albeit brief, suggest a breakthrough in the realm of individualized cancer therapies.
Source: arstechnica.com
